Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Down - Should You Sell?

Key Points

• Hikma Pharmaceuticals' shares gapped down from a previous close of $27.96 to an opening price of $26.38, reflecting a notable decline in value.
• Analysts at BNP Paribas have issued an "outperform" rating for Hikma Pharmaceuticals, signaling potential for positive performance despite the recent stock decline.
• The company's 50-day and 200-day simple moving averages are $27.73 and $26.99, respectively, indicating a general trend of weakening stock performance.

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF - Get Free Report)'s share price gapped down prior to trading on Wednesday . The stock had previously closed at $27.96, but opened at $26.38. Hikma Pharmaceuticals shares last traded at $26.38, with a volume of 200 shares changing hands.

Analysts Set New Price Targets

Separately, BNP Paribas assumed coverage on Hikma Pharmaceuticals in a report on Tuesday, May 13th. They issued an "outperform" rating on the stock.

Hikma Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.65 and a current ratio of 1.14. The business has a 50 day moving average of $27.68 and a 200 day moving average of $27.00.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.